Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

被引：0
|
作者：
Strober, Bruce [1 ,2 ]
Paul, Carle [3 ]
Blauvelt, Andrew [4 ]
Thaci, Diamant [5 ]
Elewski, Boni [6 ]
White, Katy [7 ]
Vanvoorden, Veerle [7 ]
Deherder, Delphine [7 ]
Staelens, Fabienne [7 ]
Spelman, Lynda [8 ]
Eyerich, Kilian [9 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Cent Connecticut Dermatol Res, Cromwell, CT USA
[3] Paul Sabatier Univ, Toulouse, France
[4] Oregon Med Res Ctr, Portland, OR USA
[5] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH 44106 USA
[7] UCB Pharma, Brussels, Belgium
[8] Verac Clin Res, Woolloongabba, Qld, Australia
[9] Tech Univ Munich, Munich, Germany
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2022年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [21] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Papp, Kim A.
    de Vente, Saskia
    Zeng, Jiewei
    Flack, Mary
    Padilla, Byron
    Tyring, Stephen K.
    DERMATOLOGY AND THERAPY, 2021, 11 (02) : 487 - 497
  • [22] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study
    Paller, Amy
    Becker, Emily
    de Lucas, Raul
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Barcellona, Claire
    Maes, Peter
    Fiorillo, Loretta
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB120 - AB120
  • [23] Safety and efficacy of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study
    Paller, A.
    Becker, E.
    de Lucas, R.
    Paris, M.
    Zhang, W.
    Zhang, Z.
    Barcellona, C.
    Maes, P.
    Fiorillo, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 174 - 175
  • [24] Safety of efalizumab therapy in patients with moderate to severe psoriasis - An open-label extension of a phase IIIb trial
    Hamilton, Tiffani
    Menter, Alan
    Caro, Ivor
    Compton, Peter
    Sobell, Jeffrey
    Papp, Kim A.
    DRUG SAFETY, 2008, 31 (08) : 715 - 726
  • [25] Bimekizumab efficacy and safety through 2 years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
    Penas, Pablo Fernandez
    Gordon, Kenneth B.
    Armstrong, April W.
    Lebwohl, Mark
    Blauvelt, Andrew
    Paul, Carle
    Wang, Maggie
    Vanvoorden, Veerle
    Madden, Cynthia
    Gomez, Natalie Nunez
    Deherder, Delphine
    Thaci, Diamant
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 20 - 20
  • [26] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial
    Strober, Bruce E.
    Pinter, Andreas
    Warren, Richard B.
    Blauvelt, Andrew
    Sebastian, Michael
    De Cuyper, Dirk
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB138 - AB138
  • [27] Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
    Baraliakos, Xenofon
    Deodhar, Atul
    Dougados, Maxime
    Oortgiesen, Marga
    de Peyrecave, Natasha
    Bauer, Martin
    Vaux, Thomas
    Fleurinck, Carmen
    van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [28] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
    Kern, Johannes S.
    Feldman, Steven R.
    Gottlieb, Alice B.
    Soung, Jennifer
    Augustin, Matthias
    Gisondi, Paolo
    Peterson, Luke
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Gomez, Natalie Nunez
    Warren, Richard B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 19
  • [29] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
    Feldman, Steven R.
    Gottlieb, Alice B.
    Soung, Jennifer
    Augustin, Matthias
    Gisondi, Paolo
    Peterson, Luke
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Gomez, Natalie Nunez
    Warren, Richard B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
  • [30] Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
    Cestari, Tania F.
    Souza, Cacilda da Silva
    Azulay-Abulafia, Luna
    Romiti, Ricardo
    Carvalho, Andre V. E.
    de Castro, Caio Cesar Silva
    Marques, Silvio Alencar
    Antonio, Joao Roberto
    Fabricio, Lincoln
    Soliman, Ahmed M.
    Wu, Tianshuang
    Sinvhal, Ranjeeta
    Stakias, Vassilis
    Song, Alexandra P.
    Kalabic, Jasmina
    Martin, Naomi
    Oyafuso, Luiza Keiko Matsuka
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2025, 100 (02) : 260 - 271
12345